Home » Stocks » PARD

Poniard Pharmaceuticals, Inc. (PARD)

Stock Price: $0.0460 USD -0.0084 (-15.44%)
Updated Oct 23, 2020 2:47 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 68,936
Revenue (ttm) n/a
Net Income (ttm) -16.23M
Shares Out 1.50M
EPS (ttm) -3.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.0460
Previous Close $0.0544
Change ($) -0.0084
Change (%) -15.44%
Day's Open 0.0460
Day's Range 0.0460 - 0.0460
Day's Volume 125
52-Week Range 0.0127 - 0.1

More Stats

Market Cap 68,936
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 1.50M
Float n/a
EPS (basic) n/a
EPS (diluted) -3.79
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 47,723
Short Ratio 2.56
Short % of Float n/a
Beta 1.43
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 0.10
Revenue n/a
Operating Income n/a
Net Income -16.23M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -46.03%
ROE -210.37%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$80.00*
Low
80.0
Current: $0.0460
High
80.0
Target: 80.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Poniard Pharmaceuticals, Inc.
Country United States
Employees 7

Stock Information

Ticker Symbol PARD
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: PARD
IPO Date August 11, 1988

Description

Poniard Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic colorectal cancer and castration-resistant prostate cancer; and a Phase I study evaluating an oral formulation of picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in September 2006. Poniard Pharmaceuticals, Inc. was founded in 1984 and is based in Seattle, Washington.